| Idelalisib studied in …STUDIED_INderived57 of 57show fewer |
|---|
| → studied in | NCT06846671Phase 3 · recruiting A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218341Phase 4 · recruiting A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02970318Phase 3 · active not recruiting A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · 57 trials list this drug (7 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01644799Phase 1 · completed Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma · 57 trials list this drug (7 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01838434Phase 1 · completed Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma · 57 trials list this drug (7 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07139873Phase 3 · recruiting A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02787369Phase 1 · active not recruiting ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL · 57 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04666038Phase 3 · active not recruiting Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02135133Phase 2 · completed A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03133221Phase 2 · completed 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation · 57 trials list this drug (7 active) | — | — | B-Cell Malignant Neoplasm,Non-Hodgkin Lymphoma,Small Lymphocytic Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02457598Phase 1 · terminated Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies · 57 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03890289Phase 2 · terminated Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma · 57 trials list this drug (7 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06205290Phase 3 · withdrawn A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies · 57 trials list this drug (7 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03151057Phase 1 · terminated Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia,Follicular Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 57 trials list this drug (7 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03257722Phase 1/Phase 2 · terminated Pembrolizumab + Idelalisib for Lung Cancer Study · 57 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04699461Phase 2 · terminated Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma · 57 trials list this drug (7 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02962401Phase 2 · completed Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia · 57 trials list this drug (7 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02536300Phase 3 · terminated Dose Optimization Study of Idelalisib in Follicular Lymphoma · 57 trials list this drug (7 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05725200Phase 2 · recruiting Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · 57 trials list this drug (7 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02968563Phase 2 · completed Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02639910Phase 2 · completed Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi · 57 trials list this drug (7 active) | — | — | Leukemia,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03568929completed Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma · 57 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01620216Phase 2 · terminated Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia · 57 trials list this drug (7 active) | — | — | Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03576443Phase 2 · completed Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma · 57 trials list this drug (7 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742323Phase 1/Phase 2 · terminated REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia · 57 trials list this drug (7 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02928510terminated Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma · 57 trials list this drug (7 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02242045Phase 1 · completed Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01088048Phase 1 · completed Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia,Indolent Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02538614Phase 1 · terminated Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01796470Phase 2 · terminated Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia,Diffuse Large B-Cell Lymphoma,Indolent Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02779283Phase 1 · completed Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia · 57 trials list this drug (7 active) | — | — | Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01569295Phase 3 · completed Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02739360Phase 4 · terminated Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 · 57 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02603445Phase 1 · completed Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL · 57 trials list this drug (7 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01090414Phase 1/Phase 2 · terminated An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study · 57 trials list this drug (7 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01539291Phase 3 · terminated Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01659021Phase 3 · terminated Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01282424Phase 2 · completed Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas · 57 trials list this drug (7 active) | — | — | Small Lymphocytic Lymphoma,Follicular Lymphoma,Lymphoplasmacytic Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01539512Phase 3 · completed A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02258529Phase 2 · terminated Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma · 57 trials list this drug (7 active) | — | — | Small Lymphocytic Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03582098completed Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03349346Phase 1 · withdrawn Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents · 57 trials list this drug (7 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01306643Phase 1/Phase 2 · completed Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma · 57 trials list this drug (7 active) | — | — | Small Lymphocytic Lymphoma,Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01393106Phase 2 · completed Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma · 57 trials list this drug (7 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01980875Phase 3 · terminated Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01980888Phase 3 · terminated Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02044822Phase 2 · terminated Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion · 57 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01203930Phase 2 · terminated A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01732913Phase 3 · terminated Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas · 57 trials list this drug (7 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01732926Phase 3 · terminated Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas · 57 trials list this drug (7 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02662296Phase 2 · withdrawn Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant · 57 trials list this drug (7 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Prolymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02439138Phase 2 · terminated Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia · 57 trials list this drug (7 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02136511approved for marketing Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01659047Phase 2 · withdrawn A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia · 57 trials list this drug (7 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00710528Phase 1 · completed Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies · 57 trials list this drug (7 active) | — | — | Lymphoma,Multiple Myeloma,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |